menu
    • menu
    [{"orgOrder":0,"company":"The Aurum Institute NPC","sponsor":"Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sutezolid","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The Aurum Institute NPC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Aurum Institute NPC \/ Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance","highestDevelopmentStatusID":"9","companyTruncated":"The Aurum Institute NPC \/ Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance"}]

    Find Clinical Drug Pipeline Developments & Deals for Sutezolid

    Menu

    Sutezolid

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Aurum Institute NPC

                            Country arrow
                            World Drug Safety EU
                            Not Confirmed

                            The Aurum Institute NPC

                            Country arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sutezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Saúde, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pan-TB Regimen Targeting Host and Microbe

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Sutezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Saúde, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Michael Hoelscher

                            Country arrow
                            World Drug Safety EU
                            Not Confirmed

                            Michael Hoelscher

                            Country arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sutezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : European & Developing Countries Clinical Trials Partnership | Sequella, Inc. | Radboud University Medical Center | University of California, San Francisco | German Federal Ministry of Education and Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PanACEA Sutezolid Dose-finding and Combination Evaluation

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2019

                            Lead Product(s) : Sutezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : European & Developing Countries Clinical Trials Partnership | Sequella, Inc. | Radboud University Medical Center | University of California, San Francisco | German Federal Ministry of Education and Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sequella, Inc.

                            Country arrow
                            World Drug Safety EU
                            Not Confirmed

                            Sequella, Inc.

                            Country arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sutezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole B...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 21, 2010

                            Lead Product(s) : Sutezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth